Heron Therapeutics (HRTX) Misses Q2 EPS by 2c

Heron Therapeutics (NASDAQ: HRTX) reported Q2 EPS of ($0.03), $0.02 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $37.67 million versus the consensus estimate of $42.13 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Trilogy Metals signs $35.6M investment deal with U.S. Dept. of War
• Flowers Foods (FLO) files mixed shelf